ArticleLupus science & medicine2026
Development and validation of a lectin-based assay for detection of IgG Fc glycosylation as a biomarker in lupus nephritis.
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLupus nephritis (LN) is a devastating complication of systemic lupus erythematosus (SLE). Aberrant IgG glycosylation drives podocyte injury and is a robust marker for LN. The primary method for detecting glycosylation is limited to mass spectrometry, but it is not suitable for clinical applications due to its complexity and high cost.
methodsWe developed and optimised a lectin-based enzyme-linked assay to detect IgG glycan residues. Lectins were selected based on the glycan structures detected in a SLE cohort and were differentially expressed in SLE with and without nephritis. 96-well plates were coated with protein L. Blocking solutions for each lectin were selected from 5% bovine serum albumin (BSA), deglycosylated BSA (deBSA) and carbo-free blocking solution. IgG standards range was optimised starting from 0 to 20 µg/mL. Fucose was detected by
resultsThe selected lectins produced reproducible standard curves with strong linearity. ELISA assays performed using IgG from a healthy donor, and a patient with LN revealed glycan differences that were consistent with mass spectrometry data and within range of the standard curves. While the AAL (fucose) binding did not differ among different SLE subgroups, ECL (galactose) binding showed significant differences in patients with active LN compared with those with active non-renal SLE and quiescent disease. SNA (sialic acid) binding also distinguished patients with active LN from those with quiescent SLE; however, it did not discriminate between renal and non-renal SLE.
conclusionsThe developed lectin-ELISA assay can detect glycosylation characteristics of IgG in a more cost-effective, clinically applicable manner compared with mass spectrometry. Our validation data suggest the potential of ECL binding assays to help diagnose and monitor patients with LN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.